Evaxion to announce business update and third quarter 2024 financial results on October 31
28 Ottobre 2024 - 1:00PM
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S
(NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company
specializing in developing AI-Immunology™ powered vaccines, will
provide a business update and report its third quarter 2024
financial results on Thursday October 31, 2024, before opening of
the Nasdaq CM.
Evaxion’s Executive
Management will host a conference call and webcast the same day at
13:30 CET/08:30 EST, presenting the update and results as well as
taking questions. This event is free, open to the public and
encouraged.
To join the conference
call, listen to the presentation and ask verbal questions, please
register in advance via this link to receive the dial-in telephone
numbers and a unique PIN code. The call can be accessed 15 minutes
prior to the start of the live event.
To join the webcast,
please click on this link. The webcast recording will be available
on our website shortly after the event.
Contact
information
Evaxion Biotech A/S Mads Kronborg Vice
President, Investor Relations & Communication +45 53 54 82
96 mak@evaxion-biotech.com
About
EVAXION
Evaxion Biotech A/S is
a pioneering TechBio company based upon its AI platform,
AI-Immunology™. Evaxion’s proprietary and scalable AI prediction
models harness the power of artificial intelligence to decode the
human immune system and develop novel immunotherapies for cancer,
bacterial diseases, and viral infections. Based upon
AI-Immunology™, Evaxion has developed a clinical-stage oncology
pipeline of novel personalized vaccines and a preclinical
infectious disease pipeline in bacterial and viral diseases with
high unmet medical needs. Evaxion is committed to transforming
patients’ lives by providing innovative and targeted treatment
options. For more information about Evaxion and its groundbreaking
AI-Immunology™ platform and vaccine pipeline, please visit our
website.
Forward-looking
statement
This announcement
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. The
words “target,” “believe,” “expect,” “hope,” “aim,” “intend,”
“may,” “might,” “anticipate,” “contemplate,” “continue,”
“estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can
have,” “likely,” “should,” “would,” “could,” and other words and
terms of similar meaning identify forward-looking
statements. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
factors, including, but not limited to, risks related to: our
financial condition and need for additional capital; our
development work; cost and success of our product development
activities and preclinical and clinical trials; commercializing any
approved pharmaceutical product developed using our AI platform
technology, including the rate and degree of market acceptance of
our product candidates; our dependence on third parties including
for conduct of clinical testing and product manufacture; our
inability to enter into partnerships; government regulation;
protection of our intellectual property rights; employee matters
and managing growth; our ADSs and ordinary shares, the impact of
international economic, political, legal, compliance, social and
business factors, including inflation, and the effects on
our business from the worldwide ongoing COVID-19 pandemic and the
ongoing conflict in the region surrounding Ukraine and Russia and
the Middle East; and other uncertainties affecting our business
operations and financial condition. For a further discussion of
these risks, please refer to the risk factors included in our most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available
at www.sec.gov. We do not assume any obligation to update
any forward-looking statements except as required by
law.
Grafico Azioni Evaxion Biotech AS (NASDAQ:EVAX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Evaxion Biotech AS (NASDAQ:EVAX)
Storico
Da Dic 2023 a Dic 2024
